Bristol Myers Squibb Co (BMY) Stock Analysis and Metrics

Bristol Myers Squibb

NYSE: BMY

$60.74 ▲ +0.23 (+0.38%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

ROIC (Qtr)0.00

Total Debt (Qtr)44.46 Bn

Revenue Growth (1y) (Qtr)2.57

Add ratio to table…

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. The company operates as a biopharmaceutical firm focused on transformational therapies in oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas where it aims to create long-term value. Bristol-Myers Squibb generates revenue primarily…

Investment Thesis

▲ Bull case

Bristol Myers Squibb’s CELMoD platform, particularly mezigdomide, is positioned to become a transformative standard of care in relapsed or refractory multiple myeloma, with the SUCCESSOR-2 trial demonstrating a 52% reduction in risk of disease progression or death (HR: 0.48) and a median PFS of 18 months versus 8.3 months for the control arm. This represents a clinically meaningful and statistically significant improvement, underpinned by strong response rates (80.2% ORR, 26.7% CR or better) and a manageable safety profile consistent with prior data. Crucially, mezigdomide’s oral administration and ability to be used across diverse care settings—including community oncology clinics where most myeloma patients are treated—addresses a major unmet need for low-burden regimens. Management’s confidence in replacing Revlimid and Pomalyst in later lines of therapy is reinforced by the drug’s potent mechanism of action targeting cereblon-mediated degradation of Ikaros and Aiolos, with ongoing trials (SUCCESSOR-1 and successor studies) poised to expand its utility. The FDA’s acceptance of iberdomide’s filing with breakthrough therapy designation and priority review (PDUFA August 17) further validates the platform, creating near-term catalysts that could drive rapid adoption and offset generic erosion in legacy myeloma franchises.
The strategic collaboration with Hengrui Pharma represents a hidden catalyst with substantial long-term growth potential that management did not heavily promote in the earnings call. The agreement includes up to $950 million in upfront and milestone payments, with a potential total value of $15.2 billion if joint discovery programs and commercial milestones are achieved. BMS gains exclusive worldwide rights to Hengrui-originated assets outside mainland China, Hong Kong, and Macau, while securing access to Hengrui’s discovery engine and early-stage development expertise. This partnership allows BMS to leverage China’s cost and speed advantages in early innovation—where studies can be conducted in half the time and at one-third of the cost—without ceding global commercial rights. Unlike traditional licensing deals, this reciprocal model enables BMS to both in-license promising assets and co-develop novel molecules, positioning the company to tap into a growing source of early-stage pipeline innovation. Given that over half of large pharma licensing deals now originate from China (up from 39% in 2025), this collaboration provides structural access to a critical innovation hub that could significantly augment BMS’s mid- and late-stage pipeline over the next decade, particularly in oncology, hematology, and immunology.
Milvexian’s Factor XI inhibitor program for atrial fibrillation and secondary stroke prevention is underappreciated by the market despite its differentiated bleeding profile and strong trial design. The AFib trial is fully powered with 20,500 patients, designed to show noninferiority to apixaban on efficacy (with margins of 0.8% to 1.3%) and superiority on bleeding reduction—a clinically meaningful endpoint that payers consistently cite as the largest cost driver in oral anticoagulation therapy. Management emphasized that the study remains on track for a year-end readout, with event-driven recruitment proceeding as planned, and highlighted Milvexian’s potential to address the significant unmet need where roughly 40% of patients who should be anticoagulated are untreated, underdosed, or discontinue therapy due to bleeding concerns with current Factor Xa inhibitors like Eliquis. A successful readout could position Milvexian as a first-in-class Option with superior safety, driving adoption in a large patient base seeking effective anticoagulation without the bleeding risks that limit Eliquis use, thereby creating a new growth vector in cardiovascular therapeutics that complements rather than cannibalizes Eliquis.

Bristol Myers Squibb’s CELMoD platform, particularly mezigdomide, is positioned to become a transformative standard of care in relapsed or refractory multiple myeloma, with the SUCCESSOR-2 trial demonstrating a 52% reduction in risk of disease progression or death (HR: 0.48) and a median PFS of 18 months versus 8.3 months for the control arm. This represents a clinically meaningful and statistically significant improvement, underpinned by strong response rates (80.2% ORR, 26.7% CR or better) and a manageable safety profile consistent with prior data. Crucially, mezigdomide’s oral administration and ability to be used across diverse care settings—including community oncology clinics where most myeloma patients are treated—addresses a major unmet need for low-burden regimens. Management’s confidence in replacing Revlimid and Pomalyst in later lines of therapy is reinforced by the drug’s potent mechanism of action targeting cereblon-mediated degradation of Ikaros and Aiolos, with ongoing trials (SUCCESSOR-1 and successor studies) poised to expand its utility. The FDA’s acceptance of iberdomide’s filing with breakthrough therapy designation and priority review (PDUFA August 17) further validates the platform, creating near-term catalysts that could drive rapid adoption and offset generic erosion in legacy myeloma franchises.
The strategic collaboration with Hengrui Pharma represents a hidden catalyst with substantial long-term growth potential that management did not heavily promote in the earnings call. The agreement includes up to $950 million in upfront and milestone payments, with a potential total value of $15.2 billion if joint discovery programs and commercial milestones are achieved. BMS gains exclusive worldwide rights to Hengrui-originated assets outside mainland China, Hong Kong, and Macau, while securing access to Hengrui’s discovery engine and early-stage development expertise. This partnership allows BMS to leverage China’s cost and speed advantages in early innovation—where studies can be conducted in half the time and at one-third of the cost—without ceding global commercial rights. Unlike traditional licensing deals, this reciprocal model enables BMS to both in-license promising assets and co-develop novel molecules, positioning the company to tap into a growing source of early-stage pipeline innovation. Given that over half of large pharma licensing deals now originate from China (up from 39% in 2025), this collaboration provides structural access to a critical innovation hub that could significantly augment BMS’s mid- and late-stage pipeline over the next decade, particularly in oncology, hematology, and immunology.
Milvexian’s Factor XI inhibitor program for atrial fibrillation and secondary stroke prevention is underappreciated by the market despite its differentiated bleeding profile and strong trial design. The AFib trial is fully powered with 20,500 patients, designed to show noninferiority to apixaban on efficacy (with margins of 0.8% to 1.3%) and superiority on bleeding reduction—a clinically meaningful endpoint that payers consistently cite as the largest cost driver in oral anticoagulation therapy. Management emphasized that the study remains on track for a year-end readout, with event-driven recruitment proceeding as planned, and highlighted Milvexian’s potential to address the significant unmet need where roughly 40% of patients who should be anticoagulated are untreated, underdosed, or discontinue therapy due to bleeding concerns with current Factor Xa inhibitors like Eliquis. A successful readout could position Milvexian as a first-in-class Option with superior safety, driving adoption in a large patient base seeking effective anticoagulation without the bleeding risks that limit Eliquis use, thereby creating a new growth vector in cardiovascular therapeutics that complements rather than cannibalizes Eliquis.

▼ Bear case

Bristol Myers Squibb faces significant near-term headwinds from the accelerating generic erosion of its legacy portfolio, particularly Revlimid and Pomalyst in multiple myeloma, which management acknowledged are under increasing pressure despite growth from newer assets like mezigdomide. While the CELMoD platform shows promise, the SUCCESSOR-2 trial’s safety profile reveals concerning rates of grade 3-4 adverse events: neutropenia in 61.1% of patients on MeziKd versus 9.1% in the control arm, and infections in 34.0% versus 15.6%, indicating a substantially higher toxicity burden than the standard carfilzomib-dexamethasone regimen. This elevated risk profile may limit real-world adoption, especially in elderly or frail patients who constitute a large portion of the relapsed/refractory myeloma population, and could deter community oncologists from prescribing despite the oral convenience. Furthermore, the company’s reliance on early-stage pipeline assets like mezigdomide and iberdomide to offset generic declines assumes rapid uptake and sustained efficacy, but the durability of response remains unproven—median OS was not reached in SUCCESSOR-2, and longer-term data from successor studies are still pending. Without clear evidence of overall survival benefit or a favorable long-term safety trajectory, the CELMoD franchise may struggle to displace entrenched standards of care, leaving BMS vulnerable to continued revenue decline from its myeloma franchise as generics gain share.
The cardiovascular franchise, particularly Eliquis, remains vulnerable to pricing and reimbursement pressures that could undermine its growth trajectory, despite first-quarter strength. While Eliquis revenue grew 13% year-over-year to $4.1 billion, management acknowledged a wholesale inventory build due to the U.S. price reduction effective at the start of the year, which they anticipate will reverse in Q2—suggesting the underlying demand may be weaker than reported sales indicate. More critically, the U.S. Supreme Court’s decision to uphold the Medicare drug price negotiation provisions of the Inflation Reduction Act exposes Eliquis to potential future price controls, as it is among the high-expenditure drugs targeted for negotiation. Although the first negotiated prices took effect this year, Eliquis has not yet been named in the initial tranche, but its inclusion in future cycles is highly likely given its Medicare spending footprint. A mandated price reduction would directly impact Eliquis’s margin profile and could trigger further wholesale and retail inventory adjustments, disrupting revenue predictability. Additionally, Milvexian’s success is not guaranteed; the trial’s reliance on historical stroke rates—which are lower than in Eliquis’s early days—could challenge the ability to demonstrate noninferiority on efficacy, and any delay in readout beyond 2026 would postpone a potential catalyst while allowing competitors to advance their own Factor XI programs.
Bristol Myers Squibb’s neuroscience franchise, particularly Cobenfy for Alzheimer’s disease psychosis, carries substantial execution and regulatory risks that are underappreciated in the current bullish narrative. While management expressed confidence in the ADP study designs and biomarker-selected populations, the requirement for imaging or blood-based biomarker positivity increases screening failures and operational complexity, potentially slowing enrollment and increasing trial costs. The company’s own admission that they need two positive studies for an optimal approval pathway—yet are relying on interim data from successor studies—creates uncertainty around the robustness of the evidence base. Furthermore, Cobenfy’s mechanism as a muscarinic receptor agonist faces scrutiny due to historical failures in this class, and although early data show promise in psychosis, the Alzheimer’s indication is notoriously difficult to win approval for due to stringent efficacy and safety thresholds. The absence of any approved Alzheimer’s psychosis treatment today underscores the scientific and regulatory hurdles, and even if approved, achieving meaningful market penetration will require overcoming entrenched antipsychotic use despite their safety limitations—a behavioral shift that is neither rapid nor guaranteed. Without clear near-term milestones beyond 2026 readouts, the franchise remains a high-risk, long-duration bet that may not deliver meaningful revenue contribution within the current investment horizon.

Bristol Myers Squibb faces significant near-term headwinds from the accelerating generic erosion of its legacy portfolio, particularly Revlimid and Pomalyst in multiple myeloma, which management acknowledged are under increasing pressure despite growth from newer assets like mezigdomide. While the CELMoD platform shows promise, the SUCCESSOR-2 trial’s safety profile reveals concerning rates of grade 3-4 adverse events: neutropenia in 61.1% of patients on MeziKd versus 9.1% in the control arm, and infections in 34.0% versus 15.6%, indicating a substantially higher toxicity burden than the standard carfilzomib-dexamethasone regimen. This elevated risk profile may limit real-world adoption, especially in elderly or frail patients who constitute a large portion of the relapsed/refractory myeloma population, and could deter community oncologists from prescribing despite the oral convenience. Furthermore, the company’s reliance on early-stage pipeline assets like mezigdomide and iberdomide to offset generic declines assumes rapid uptake and sustained efficacy, but the durability of response remains unproven—median OS was not reached in SUCCESSOR-2, and longer-term data from successor studies are still pending. Without clear evidence of overall survival benefit or a favorable long-term safety trajectory, the CELMoD franchise may struggle to displace entrenched standards of care, leaving BMS vulnerable to continued revenue decline from its myeloma franchise as generics gain share.
The cardiovascular franchise, particularly Eliquis, remains vulnerable to pricing and reimbursement pressures that could undermine its growth trajectory, despite first-quarter strength. While Eliquis revenue grew 13% year-over-year to $4.1 billion, management acknowledged a wholesale inventory build due to the U.S. price reduction effective at the start of the year, which they anticipate will reverse in Q2—suggesting the underlying demand may be weaker than reported sales indicate. More critically, the U.S. Supreme Court’s decision to uphold the Medicare drug price negotiation provisions of the Inflation Reduction Act exposes Eliquis to potential future price controls, as it is among the high-expenditure drugs targeted for negotiation. Although the first negotiated prices took effect this year, Eliquis has not yet been named in the initial tranche, but its inclusion in future cycles is highly likely given its Medicare spending footprint. A mandated price reduction would directly impact Eliquis’s margin profile and could trigger further wholesale and retail inventory adjustments, disrupting revenue predictability. Additionally, Milvexian’s success is not guaranteed; the trial’s reliance on historical stroke rates—which are lower than in Eliquis’s early days—could challenge the ability to demonstrate noninferiority on efficacy, and any delay in readout beyond 2026 would postpone a potential catalyst while allowing competitors to advance their own Factor XI programs.
Bristol Myers Squibb’s neuroscience franchise, particularly Cobenfy for Alzheimer’s disease psychosis, carries substantial execution and regulatory risks that are underappreciated in the current bullish narrative. While management expressed confidence in the ADP study designs and biomarker-selected populations, the requirement for imaging or blood-based biomarker positivity increases screening failures and operational complexity, potentially slowing enrollment and increasing trial costs. The company’s own admission that they need two positive studies for an optimal approval pathway—yet are relying on interim data from successor studies—creates uncertainty around the robustness of the evidence base. Furthermore, Cobenfy’s mechanism as a muscarinic receptor agonist faces scrutiny due to historical failures in this class, and although early data show promise in psychosis, the Alzheimer’s indication is notoriously difficult to win approval for due to stringent efficacy and safety thresholds. The absence of any approved Alzheimer’s psychosis treatment today underscores the scientific and regulatory hurdles, and even if approved, achieving meaningful market penetration will require overcoming entrenched antipsychotic use despite their safety limitations—a behavioral shift that is neither rapid nor guaranteed. Without clear near-term milestones beyond 2026 readouts, the franchise remains a high-risk, long-duration bet that may not deliver meaningful revenue contribution within the current investment horizon.

Peer Comparison

Companies in the Drug Manufacturers - General

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,066.16 Bn	42.18	14.76	43.37 Bn
2	JNJ	Johnson & Johnson	611.69 Bn	29.07	6.35	54.99 Bn
3	ABBV	AbbVie Inc.	444.34 Bn	122.04	7.07	64.53 Bn
4	AZN	Astrazeneca Plc	284.94 Bn	23.78	2,793.52	-24.45 Bn
5	MRK	Merck & Co., Inc.	224.23 Bn	25.00	3.41	49.12 Bn
6	AMGN	Amgen Inc	195.12 Bn	25.02	5.24	57.32 Bn
7	GILD	Gilead Sciences, Inc.	156.45 Bn	16.36	5.26	22.17 Bn
8	PFE	Pfizer Inc	136.01 Bn	11,334.57	5.56	64.46 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password